In vivo, Sch C markedly reduced tumor volume and weight without obvious toxicity and increased apoptosis while decreasing proliferation in tumor tissues. Sch C exerts antimelanoma effects and is associated with inhibition of PI3K/AKT/mTOR signaling and modulation of Rap1-related pathways, suggesting its potential as a therapeutic candidate for melanoma.

P1/2, N=20, Not yet recruiting, Oslo University Hospital HF

Puerarin halted the malignant progression of CRC by reprogramming tumor lipid metabolism. Puerarin thus hold promise as a clinically deployable lipid-centric agent that could synergistically potentiate conventional anticancer drugs.

More importantly, administering rapamycin, a potent inhibitor of oligodendrogenesis, during repeated fear recalls phenocopies the effects of anti-myelination on fear memory-related behavioral defects...Pharmacological treatments that inhibiting oligodendrogenesis during the recall phase represent a promising therapeutic strategy for preventing the pathological reinforcement of long-term fear memories, thereby averting the emergence of anxiety-like behaviors and social preference deficits in individuals with PTSD. Schematic image summarizing the major findings of the present study.

The underlying mechanism of this phenomenon was associated with the modulation of autophagic pathways by rapamycin, encouraging the differentiation of naïve CD4 T cells into MOG35-55-specific Tregs, as evidenced by tetramer staining. These findings provide a conceptual framework for exploring strategies aimed at promoting antigen-specific tolerance in autoimmune diseases.

P=N/A, N=292, Active, not recruiting, REVA Medical, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Mar 2029 --> Mar 2030 | Trial primary completion date: Sep 2025 --> Apr 2026

P1, N=159, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028

P2/3, N=42, Recruiting, Biodexa Limited, Rapamycin Holdings Inc. | N=32 --> 42

P2, N=6, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2026 --> Jun 2028

These converging mechanisms culminate in profound placental maladaptation, including structural abnormalities like chorangiosis and functional defects in nutrient transport mediated by hyperactive mechanistic target of rapamycin complex 1 (mTORC1) signaling. This review article provides insight into recent evidence to elucidate the meta-inflammatory environment of GDM, where modest but sustained elevations in biomarkers like Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) disrupt redox homeostasis and impair insulin signaling pathways through the activation of stress-sensitive kinases. By integrating these molecular perspectives, the article underscores the necessity of targeting the systemic inflammatory and oxidative continuum spanning pre-conception to the antenatal period through lifestyle interventions and emerging therapeutic strategies to mitigate GDM risk and improve maternal-fetal outcomes.

P3, N=88, Completed, Centre Hospitalier Universitaire, Amiens | Unknown status --> Completed

Additionally, the ability of phenformin to potentiate the antitumor effect of resveratrol and vistusertib was assessed...Our findings demonstrate that phenformin decreases the proliferation of various cancer cell lines in a dose-dependent manner and may have an ability to increase the autophagic flux in cervical cancer cells. Our findings demonstrate that phenformin decreases the proliferation of various cancer cell lines in a dose-dependent manner potentially by inducing apoptosis.